An Open Label Study to Evaluate G17DT Compared to Gemcitabine

• Status: Completed
• Trial end date: 2002-09-19
• Target enrollment: 0
• Participant gender: All

Summary

In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Advances Inc.
• Treatments: Gastrins; Gemcitabine

Criteria

Inclusion Criteria:

• A diagnosis of pancreatic adenocarcinoma, confirmed by histology or cytology, in patients not suitable for pancreatic tumor resection with curative intent.

• A diagnosis of recurrent pancreatic adenocarcinoma (previously confirmed by histology or cytology) in patients who have had a primary tumor resection.

• Male or female patients over 18 years of age.

• Laboratory values within the following ranges at screening:

Serum creatinine < 1.25 times upper limit of normal (ULN) Haemoglobin > 9.5 g/dL White blood cell (WBC) count > 3.5 x 109/L Platelets > 100 x 109/L Total bilirubin < 2.0 times ULN Aspartate transaminase (AST, SGOT) < 3 times ULN

• A life expectancy of at least 2 months.

• A negative pregnancy test at the screening visit (females of childbearing potential only).

• Signed written informed consent.

Exclusion Criteria:

• History of other malignant disease (except basal cell carcinoma or in situ carcinoma of the uterine cervix).

• Previous cytotoxic chemotherapy (including gemcitabine).

• Previous radiotherapy within 30 days of baseline.

• Use of systemic (oral or injected) immunosuppressants, including corticosteroids, within 30 days prior to the baseline visit. Inhaled corticosteroids for chronic obstructive pulmonary disease or asthma were permitted.

• Females of child bearing potential who are pregnant, lactating, or who are planning to become pregnant during the period of the study.

• Participation in another study involving an investigational drug within 90 days of baseline.